Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Julia Hippisley-Cox, professor of clinical epidemiology at the University of Oxford, who is not associated with the development of the Oxford/AstraZeneca vaccine, said that while the link with Guillain-Barré...
...This is not just a recent phenomenon: Adam quotes Mark Jones, former director of London’s V&A, on Richard Wallace (1818-90), founder of the Wallace Collection, who “was an outsider, because of being illegitimate...
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...And don’t miss the lightweight, compostable stools and lights designed by Sebastian Cox and Ninela Ivanova, made from green-wood waste bound together with mycelium fungus....
...Morgan and Morgan Stanley are serving as Allergan’s financial advisors for the transaction with Cleary Gottlieb Steen & Hamilton LLP, Latham & Watkins LLP and Arthur Cox acting as its legal advisors....
...Asset managers are preparing for the arrival of Ucits V in March, which will introduce new rules on asset managers’ pay....
...JPMorgan and Morgan Stanley are Allergan’s financial advisers, while Cleary Gottlieb Steen & Hamilton, Latham & Watkins, and Arthur Cox are giving legal advice....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Defence lawyers hinge their argument on a leading 1983 Supreme Court decision called Dirks v. SEC....
...Its top 10 investments now include: Pfizer, the US pharmaceuticals group; Enterprise Products Partners, a US energy group; and Diageo, the British drinks group....
...But Katherine Garrett-Cox, chief executive of investment company Alliance Trust, suggests high-yield stocks can even be a stopgap holding for growth-oriented investors....
...” … One of the largest spin-off processes being closely followed by bankers is that of Pfizer, the US pharmaceutical group....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Acquired when Pfizer bought Pharmacia in a takeover completed in 2000, Bextra, a painkiller in the same Cox-2 class as Merck’s Vioxx, was one of two drugs drawn to the attention of regulators and lawyers...
...Katherine Garrett-Cox Became chief executive of Alliance Trust this year, after joining in 2007....
...At Pfizer, Hank McKinnell’s early departure last year was accompanied by a severance package of more than $200m....
...They will also share development of some Pfizer obesity and diabetes drugs....
...It prompted intense re-examination of US drug safety regulation and pushed all cox-2 drugs but one - Celebrex, by US drugmaker Pfizer - off the market. Merck faces nearly 30,000 lawsuits over Vioxx....
...Since first appearing in 1999, Vioxx and other cox-2 drugs such as Pfizer’s Celebrex and Bextra had been billed as super aspirins - better and safer than older painkillers....
International Edition